Literature DB >> 12789282

Molecular plasticity of human melanoma cells.

Mary J C Hendrix1, Elisabeth A Seftor, Angela R Hess, Richard E B Seftor.   

Abstract

The molecular analysis of tumors, such as melanoma, has benefited significantly from microarray technology that can facilitate the classification of tumors based on the differential expression of genes. The data summarized in this review describe the molecular profile of aggressive cutaneous and uveal melanoma cells as that of multiple phenotypes similar to a pluripotent, embryonic-like stem cell. A noteworthy example of the plasticity of the aggressive melanoma cell phenotype is demonstrated by the ability of these tumor cells to engage in vasculogenic mimicry and neovascularization. A review of the current evidence demonstrating important cellular and molecular determinants of melanoma vasculogenic mimicry is presented. In addition, novel signaling pathways are discussed, involving VE-cadherin, EphA2, FAK, and PI 3-kinase, which promote cell migration, invasion, and matrix remodeling. The observations summarized in this review describe some of the key molecular events that regulate the process of melanoma vasculogenic mimicry and identify new signal transduction pathways that can serve as putative targets for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12789282     DOI: 10.1038/sj.onc.1206447

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  78 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

2.  Biomimetic hydrogels with immobilized ephrinA1 for therapeutic angiogenesis.

Authors:  Jennifer E Saik; Daniel J Gould; Aakash H Keswani; Mary E Dickinson; Jennifer L West
Journal:  Biomacromolecules       Date:  2011-06-15       Impact factor: 6.988

Review 3.  Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications.

Authors:  Balázs Döme; Mary J C Hendrix; Sándor Paku; József Tóvári; József Tímár
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

Review 4.  Essential roles of EphB receptors and EphrinB ligands in endothelial cell function and angiogenesis.

Authors:  Ombretta Salvucci; Giovanna Tosato
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

Review 5.  CD133-targeted niche-dependent therapy in cancer: a multipronged approach.

Authors:  Anthony B Mak; Caroline Schnegg; Chiou-Yan Lai; Subrata Ghosh; Moon Hee Yang; Jason Moffat; Mei-Yu Hsu
Journal:  Am J Pathol       Date:  2014-02-28       Impact factor: 4.307

6.  Induction of Vasculogenic Mimicry Overrides VEGF-A Silencing and Enriches Stem-like Cancer Cells in Melanoma.

Authors:  Caroline I Schnegg; Moon Hee Yang; Subrata K Ghosh; Mei-Yu Hsu
Journal:  Cancer Res       Date:  2015-03-13       Impact factor: 12.701

Review 7.  The role of altered cell-cell communication in melanoma progression.

Authors:  Nikolas K Haass; Keiran S M Smalley; Meenhard Herlyn
Journal:  J Mol Histol       Date:  2004-03       Impact factor: 2.611

8.  Plasticity underlies tumor progression: role of Nodal signaling.

Authors:  Thomas M Bodenstine; Grace S Chandler; Richard E B Seftor; Elisabeth A Seftor; Mary J C Hendrix
Journal:  Cancer Metastasis Rev       Date:  2016-03       Impact factor: 9.264

Review 9.  Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?

Authors:  Michael Hölzel; Anton Bovier; Thomas Tüting
Journal:  Nat Rev Cancer       Date:  2013-03-28       Impact factor: 60.716

10.  Identification of cells initiating human melanomas.

Authors:  Tobias Schatton; George F Murphy; Natasha Y Frank; Kazuhiro Yamaura; Ana Maria Waaga-Gasser; Martin Gasser; Qian Zhan; Stefan Jordan; Lyn M Duncan; Carsten Weishaupt; Robert C Fuhlbrigge; Thomas S Kupper; Mohamed H Sayegh; Markus H Frank
Journal:  Nature       Date:  2008-01-17       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.